2 min read
ASCO Annual Meeting
Meet Veristat at the 2025 ASCO Annual Meeting
Advancing Oncology Therapies for Patients in Need
Veristat is proud to...
3 min read
July 2021
Each month, Veristat's regulatory team tracks and shares a selection of new Regulatory Guidance updates from the US Food & Drug Administration (FDA) that are pertinent to the governance of clinical trials and drug, biologic, or medical device development and approval. Below are the relevant links to updates provided for both COVID-19 related and non-COVID-19 related programs in July 2021.
New FDA Guidance Documents:
Field Alert Report Submission: Questions and Answers Guidance for Industry (published 22July2021)
Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI) (published 07July2021)
Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry (published 01July2021)
Evaluating Cancer Drugs in Patients with Central Nervous System Metastases (published 01July2021)
New Draft Guidance Documents:
Rabies: Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry (published 28July2021)
Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications (published 01July2021)
EMA updates reflection paper on GMP responsibilities of marketing authorization holders (published 29July2021)
FDA approves Semglee as first biosimilar interchangeable insulin (published 28July2021)
FDA sets deadline for study data technical rejection criteria (published 28July2021)
EMA addresses comparative quality assessment methods (published 27July2021)
ICH releases widely anticipated guidance on continuous manufacturing (published 27July2021)
FDA’s revised MAPP outlines procedures for generic drug labeling changes (published 27July2021)
FDA declines to extend nitrosamine risk assessment deadline (published 26July2021)
EMA adopts guideline on quality documentation for drug-device combination products (published 26July2021)
FDA seeks new members for Patient Engagement Collaborative (published 23July2021)
FDA finalizes guidance on field alert reports (published 22July2021)
FDA seeks global shift to include pregnant women in medical research (published 21July2021)
House committee advances bills on advanced manufacturing, opioids and more (published 21July2021)
CBER targets four stem cell firms with untitled letters (published 20July2021)
AAM: Medicare Part D plans slow to adopt generics (published 19July2021)
Kineret under review by EMA for some COVID patients (published 19July2021)
PIC/S adopts guidance on PQS risk-based change management, COVID-19 risk assessments (published 16July2021)
MHRA announces streamlined clinical trial review process (published 16July 2021)
Industry consortium releases blueprint for DSCSA tracking systems (published 16July2021)
MDCG posts guidance on UDI integration within a QMS (published 15July2021)
Long-awaited ICH continuous manufacturing guideline coming soon (published 15July2021)
Upcoming ICH guidelines should ease post-approval changes for analytical methods ( published 14July2021)
MDCG offers guidance on IVDR codes (published 13July2021)
FDA sees different tactics were successful in established conditions pilot (published 13July2021)
EMA guidelines highlight changes to IMPs triggering notification to regulators (published 12July2021)
Biden’s competition order directs FDA on biosimilars, importation and OTC hearing aids (published 12July2021)
CBER Q&A addresses stem cell enforcement questions (published 12July2021)
Woodcock calls for investigation into Aduhelm approval (published 09July2021)
EMA's PRAC weighs in on more vaccine side effects (published 09July2021)
FDA trims Aduhelm's indicated population (published 08July2021)
Appeals court overturns FDA’s ban of electric shock device (published 08July2021)
FDA calls for new warning labels on hydroxyethyl starch products (published 08July2021)
EMA updates Q&A on nitrosamine assessment and testing (published 07July2021)
MDUFA V negotiations press on with breakdown over TPLC proposal (published 07July2021)
FDA finalizes guidance on studying CNS metastases in cancer trials (published 06July2021)
FDA finalizes long-awaited UDI guidance (published 06July2021)
PIC/S finalizes GMP data integrity guidance (published 02July2021)
DIA: Woodcock, other top officials tout benefits of master protocols, want momentum to continue post-COVID (published 02July2021)
FDA issues draft guidance for transdermal adhesion systems (published 01July2021)
House Appropriations advances FDA funding bill (published 01July2021)
FDA issues final guidance on providing regulatory submissions in alternate electronic formats (published 01July2021)
-
Review the recording from our webinar: How to Better Plan Your Virtual Clinical Trial
-
Learn how Veristat experts can help you better plan your decentralized clinical trials: Adopting Decentralized Clinical Trials
- Download our COVID-19 Guide on Strategies For Success During the COVID-19 Era
- Read our infographic to Understand FDA Expedited Pathways for Accelerating Time-to-Market for Products Treating Serious Conditions or Unmet Medical Needs
- Download the Infographic explaining the Types of FDA Meetings with CDER and CBER